EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tocilizumab Use and Outcomes in Hospitalized COVID-19 Patients During the Initial Pandemic Peak in Peru: A Real-World Retrospective Study

Enrique Morello Bustios, Socorro Castro, César Ticona, Ricardo Sánchez, Mario Cornejo, Jorge Ravelo, Edward Smith, Sergio Sánchez-Gambetta, Christian Barrenechea, Eduardo Gotuzzo, Martín Casapía

COVID · 03.11.2026 · 6 (11) · 197

DOI: 10.3390/covid6110197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift COVID, online erschienen am 03.11.2026. Verfasst von Enrique Morello Bustios und 10 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche Ltd..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tocilizumab was used as emergency treatment for COVID-19 in Peru during 2020, before randomized clinical trial evidence supporting its use became available. Documenting real-world experiences of its implementation in resource-constrained health systems provides relevant insights for pandemic preparedness.

Methods

Retrospective cohort study of 242 patients hospitalized with COVID-19 who received tocilizumab at seven sites in Peru (March–September 2020). Clinical characteristics, tocilizumab use, and adverse events were described (primary objective). A Cox proportional-hazards model was used as a secondary analysis to explore the association between tocilizumab initiation within the first 3 days of hospitalization (days 1–3) vs. later and all-cause mortality.

Results

79.8% (n = 193) patients were male; mean age was 59.0 years (SD: 13.0); 43.0% died. The median cumulative tocilizumab dose was 400 mg (IQR: 400–600 mg), lower than the currently recommended weight-based regimen (8 mg/kg; maximum 800 mg per infusion); 86.4% received a single dose. In the adjusted Cox model, early tocilizumab use was not significantly associated with mortality (HR: 1.09; 95%CI: 0.67–1.75; p = 0.72). The proportional-hazards assumption was met globally. Adverse events of any cause (not assessed for causality) were recorded during hospitalization in 56 (23.1%) patients; the most frequent MedDRA category was respiratory, thoracic, and mediastinal disorders (n = 16).

Conclusions

This Peruvian cohort documents how tocilizumab was used, in terms of timing and dose, during the first pandemic wave in a resource-constrained setting. In the absence of an untreated comparator, these data do not allow inferences on the contribution of tocilizumab to mortality, ICU admission, or adverse events.

Förderung

  • F. Hoffmann-La Roche Ltd.

Zitieren

APA

Bustios, E. M., Castro, S., Ticona, C., Sánchez, R., Cornejo, M., Ravelo, J., Smith, E., Sánchez-Gambetta, S., Barrenechea, C., Gotuzzo, E., & Casapía, M. (2026). Tocilizumab Use and Outcomes in Hospitalized COVID-19 Patients During the Initial Pandemic Peak in Peru: A Real-World Retrospective Study. COVID, 6(11), 197. https://doi.org/10.3390/covid6110197

Vancouver

Bustios EM, Castro S, Ticona C, Sánchez R, Cornejo M, Ravelo J, et al. Tocilizumab Use and Outcomes in Hospitalized COVID-19 Patients During the Initial Pandemic Peak in Peru: A Real-World Retrospective Study. COVID. 2026;6(11):197. doi:10.3390/covid6110197

BibTeX
@article{Bustios2026,
  author = {Bustios, Enrique Morello and Castro, Socorro and Ticona, César and Sánchez, Ricardo and Cornejo, Mario and Ravelo, Jorge and Smith, Edward and Sánchez-Gambetta, Sergio and Barrenechea, Christian and Gotuzzo, Eduardo and Casapía, Martín},
  title = {Tocilizumab Use and Outcomes in Hospitalized COVID-19 Patients During the Initial Pandemic Peak in Peru: A Real-World Retrospective Study},
  journal = {COVID},
  year = {2026},
  volume = {6},
  number = {11},
  pages = {197},
  doi = {10.3390/covid6110197}
}
Kostenlos starten →